Showing results (1751-1760 of 3,660) with videos related to

Sort By:
Pageof 366
Breast (Edinburgh, Scotland)|August 22, 2026
Biomarker-based risk stratification for predicting late recurrence and benefit of extended endocrine therapy: A secondary analysis of the IDEAL trialTejal D Durgekar, Shyamili Goutham, Xi Zhang, et al.
Breast (Edinburgh, Scotland)|August 26, 2026
Breast cancer-related fatigue: Mechanisms, biomarkers, risk factors, and intervention strategiesChaofan Zhao, Qi Qiu, Yuanyuan Wang, et al.
Breast (Edinburgh, Scotland)|September 2, 2026
Cost-effectiveness of abbreviated breast MRI and contrast-enhanced mammography for women with extremely dense breasts in a national breast cancer screening program: a micro-simulation studyMengmeng Li, Marcel J W Greuter, Keris Poelhekken, et al.
Breast (Edinburgh, Scotland)|July 23, 2026
[18F]FDG PET/MRI for axillary staging in node positive breast cancer patients receiving primary systemic therapy. A prospective single arm trialRosa Di Micco, Edoardo Botteri, Carla Canevari, et al.
Breast (Edinburgh, Scotland)|August 27, 2026
Oncotype DX-guided vs physician-directed chemotherapy and survival in HR+/HER2- breast cancerJingkun Li, Xinhao Han, Yan Zhuang, et al.
Breast (Edinburgh, Scotland)|August 28, 2026
Revisiting HER2-negative breast cancer in the era of HER2-low and HER2-ultralow expression: Assessment of interobserver variabilityXiao Huang, Sarah Anderson, Valeria Dal Zotto, et al.
Breast (Edinburgh, Scotland)|September 15, 2026
Pembrolizumab plus chemotherapy followed by pembrolizumab in participants in Asia with early triple-negative breast cancer: An updated subgroup analysis of the KEYNOTE-522 randomized clinical trialYeon Hee Park, Rina Hui, Seock-Ah Im, et al.
Breast (Edinburgh, Scotland)|October 2, 2026
Impact of anti-HER2 therapies on potentially avoidable deaths from stage II and III HER2-positive breast cancer in the Brazilian public healthcare systemAndré Mattar, Francisco Pimentel Cavalcante, Nelson Francisco Correa-Netto, et al.
Breast (Edinburgh, Scotland)|September 30, 2026
Risk factors of immune-related adverse events in patients with early-stage breast cancer: Findings from a multi-institutional retrospective studyAlexis LeVee, Saya Jacob, Samantha Fisch, et al.
Breast (Edinburgh, Scotland)|October 29, 2026
Knowledge gaps and future perspectives for the definition, diagnostics and treatment of isolated locoregional recurrent breast cancerTess I M Snellen, Charlotte M Vervenne, Vincent O Dezentjé, et al.
Pageof 366